Sodium-Glucose Co-Transporter 2 Inhibitors: Mechanism of Action and Efficacy in Non-Diabetic Kidney Disease from Bench to Bed-Side
AM Abdelrahman, AS Awad… - Journal of Clinical …, 2024 - mdpi.com
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are currently available for the
management of type 2 diabetes mellitus. SGLT2i acts by inhibiting renal SGLT2, thereby …
management of type 2 diabetes mellitus. SGLT2i acts by inhibiting renal SGLT2, thereby …
Effect of sodium-glucose cotransporter 2 inhibitors on 24-hour ambulatory blood pressure in patients with type-2 diabetes and hypertension: an updated meta-analysis …
F Iqbal, MH Shuja, L Azam, M Amjad, KZ Manjee… - Endocrine Practice, 2024 - Elsevier
Background Sodium-glucose cotransporter 2 (SGLT2) inhibitors, initially developed for type
2 diabetes treatment, have shown potential benefits beyond glycemic control, including a …
2 diabetes treatment, have shown potential benefits beyond glycemic control, including a …
[HTML][HTML] Dapagliflozin and Blood Pressure in Patients with Chronic Kidney Disease and Albuminuria
Abstract Background and Aims Sodium–glucose cotransporter 2 inhibitors decrease blood
pressure in patients with type 2 diabetes, but the consistency and magnitude of blood …
pressure in patients with type 2 diabetes, but the consistency and magnitude of blood …
Comparison of incident hypertension between SGLT2 inhibitors vs. DPP4 inhibitors
Y Suzuki, H Kaneko, A Okada, J Komuro, K Fujiu… - Hypertension …, 2024 - nature.com
Although several randomized clinical trials have reported the potential benefit of sodium-
glucose cotransporter 2 inhibitors (SGLT2i) in reducing blood pressure (BP), whether …
glucose cotransporter 2 inhibitors (SGLT2i) in reducing blood pressure (BP), whether …
Clinical and mechanistic potential of sodium-glucose co-transporter 2 (SGLT2) inhibitors in heart failure with preserved ejection fraction
JW Ostrominski, M Vaduganathan - The American Journal of Medicine, 2024 - Elsevier
Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have emerged as an important
approach for the treatment of heart failure in patients with or without diabetes. Although the …
approach for the treatment of heart failure in patients with or without diabetes. Although the …
Integrated analysis reveals ceRNA network of cardiac remodeling by SGLT2 inhibitor in middle-aged hypertensive rats
T Xiong, Y Jia, F Tan, X Long, X Yuan, Q She… - … and Biophysical Research …, 2024 - Elsevier
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) represent an innovative class of
antidiabetic agents that have demonstrated promise in mitigating cardiac remodeling …
antidiabetic agents that have demonstrated promise in mitigating cardiac remodeling …
Ambulatory Blood Pressure Monitoring in Clinical Hypertension Management
L Malha, WB White - Hypertension, 2024 - Elsevier
Prior to the early 1970s, intraarterial recordings provided the only means of following
changes in blood pressure (BP) during the typical activities of daily living. The development …
changes in blood pressure (BP) during the typical activities of daily living. The development …
Influence of intelligent management mode based on Internet of Things on self-management ability and prognosis of elderly patients with hypertensive heart disease …
Y Xu, W Zai, M Yang, L Zhu, Y Zhang, X Fu, T Dai - Medicine, 2024 - journals.lww.com
Hypertensive heart disease was difficult to cure with drugs, and most patients had poor
compliance, leading to recurrent disease and poor quality of life. The intelligent …
compliance, leading to recurrent disease and poor quality of life. The intelligent …
Summary and a Patient Perspective on Living with Heart Failure
RE Monroe, J Thrasher - The American Journal of Medicine, 2024 - Elsevier
Chapter 4: Summary and a Patient Perspective on Living with Heart Failure - ScienceDirect
Skip to main contentSkip to article Elsevier logo Journals & Books Search RegisterSign in …
Skip to main contentSkip to article Elsevier logo Journals & Books Search RegisterSign in …
[PDF][PDF] Ингибиторы натрий-глюкозного котранспортера 2: механизмы кардиоренальной защиты
МВ Леонова - Consilium Medicum, 2024 - consilium.orscience.ru
Аннотация Ингибиторы натрий-глюкозного котранспортера 2 (иНГЛТ-2)–новый класс
гипогликемических препаратов, которые первоначально одобрены для лечения …
гипогликемических препаратов, которые первоначально одобрены для лечения …